The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.

This was the stock's second consecutive day of losses.

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

June 16 - Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

A cyber attack on the genetic testing firm saw personal information of 155,592 UK residents accessed in a major cyber attack ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

In this video, Deepa Jagadeesh, MD, staff oncologist at Cleveland Clinic, discusses results from the phase 2 ELM-2 study evaluating efficacy and safety of odronextamab in patients with relapsed or ...